News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients



5/6/2013 12:39:41 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary vaccine platform that results in a long lasting "active" immune response, announced today results from a first-in-man, Phase I/II clinical trial for its immunotherapy product candidate targeting carcinoembryonic antigen (CEA)-expressing cancers, such as colorectal cancer. The immunotherapy drug, called ETBX-011, induced an immune response in advanced colorectal cancer patients and gave encouraging overall survival results.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Etubics
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES